Trial reportFrontiers in immunology2018
Distinct Treatment Outcomes of Antiparasitic Therapy in
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Increased Natural Killer (NK)-cell cytotoxicity and Trypanosoma cruzi-specific memory B cells in subjects with discordant serology for Chagas disease.Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- Review
- Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpot.JCI insight · 2024Article
- Surviving septic patients endotyped with a functional assay demonstrate active immune responses.Frontiers in immunology · 2024Observational
- Article
- Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates.Antimicrobial agents and chemotherapy · 2023Article
- Frequency variation and dose modification of benznidazole administration for the treatment ofbioRxiv : the preprint server for biology · 2023Article
- Benznidazole treatment decreases IL-6 levels in Trypanosoma cruzi-infected human adipocytes differentiated from adipose tissue-derived stem cells.Memorias do Instituto Oswaldo Cruz · 2023Article
- A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease.Tropical medicine and infectious disease · 2021Review
- Reduced Trypanosoma cruzi-specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease.The Journal of antimicrobial chemotherapy · 2021Article
- Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?Frontiers in medicine · 2021Review
- New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.Antimicrobial agents and chemotherapy · 2020Article
- WHF IASC Roadmap on Chagas Disease.Global heart · 2020Review
- TcTASV Antigens ofThe American journal of tropical medicine and hygiene · 2019Article
- Understanding CD8Trends in parasitology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.